An unusual cause of cancer mimicry following liver transplantation
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 1
Abstract
Sirolimus is an approved anti-rejection agent following liver or kidney transplantation that works through inhibition of the mammalian target of rapamycin (mTOR). As sirolimus functions through a pathway independent of calcineurin inhibition, it may have less potential for nephrotoxicity and carcinogenesis. That being said, there are a myriad of potential adverse effects reported with sirolimus, many of which are severe and unknown or poorly understood. Herein we present a case of sirolimus causing a serious but uncommon adverse event in an adult liver transplant recipient; the adverse event in this instance unfortunately resulted in significant medical testing and morbidity. The adverse event profile of sirolimus is summarized through review of available evidence.
Authors and Affiliations
Karim Qumosani, Natasha Chandok
Keywords
Related Articles
- EP ID EP78111
- DOI -
- Views 110
- Downloads 0
Severe acute hepatitis in the dress syndrome: Report of two cases
The DRESS (drug rash, eosinophilia and systemic symptoms) syndrome, also known as DIHS (drug-induced hypersensitivity syndrome), is a severe idiosyncratic reaction to several drugs, mainly antiepileptics and antibiotics,...
Treatment of recurrent hepatitis C post-liver transplantation
Recurrent hepatitis C after liver transplantation is universal. Graft reinfection occurs rapidly, with chronic hepatitis and rapid evolution from end-stage liver disease. Within 5 years until 30% of patients with recurre...
Elevated acetaminophen level: Could it be a red herring?
Risk factors for and management of ischemic-type biliary lesions following orthotopic liver transplantation: A single center experience
Introduction. Biliary complications can cause morbidity, graft loss, and mortality after liver transplantation. The most troublesome biliary complications are ischemic-type biliary lesions (ITBL), which occur since trans...
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
Background. Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia...